CytomX Therapeutics Inc. (NASDAQ:CTMX) went down by -6.28% from its latest closing price compared to the recent 1-year high of $7.29. The company’s stock price has collected 47.93% of gains in the last five trading sessions.
Is It Worth Investing in CytomX Therapeutics Inc. (NASDAQ :CTMX) Right Now?
Plus, the 36-month beta value for CTMX is at 0.39. Opinions of the stock are interesting as 1 analysts out of 10 who provided ratings for CytomX Therapeutics Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 7 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $3.31, which is $1.52 above the current price. CTMX currently public float of 65.22M and currently shorts hold a 1.53% ratio of that float. Today, the average trading volume of CTMX was 1.26M shares.
CTMX’s Market Performance
CTMX stocks went up by 47.93% for the week, with a monthly jump of 35.61% and a quarterly performance of 8.48%, while its annual performance rate touched -75.17%. The volatility ratio for the week stands at 14.33% while the volatility levels for the past 30 days are set at 8.17% for CytomX Therapeutics Inc. The simple moving average for the period of the last 20 days is 31.14% for CTMX stocks with a simple moving average of -10.98% for the last 200 days.
Analysts’ Opinion of CTMX
Many brokerage firms have already submitted their reports for CTMX stocks, with BMO Capital Markets repeating the rating for CTMX by listing it as a “Market Perform.” The predicted price for CTMX in the upcoming period, according to BMO Capital Markets is $2.60 based on the research report published on November 14th of the current year 2022.
Wedbush, on the other hand, stated in their research note that they expect to see CTMX reach a price target of $2, previously predicting the price at $6. The rating they have provided for CTMX stocks is “Neutral” according to the report published on July 07th, 2022.
Piper Sandler gave a rating of “Neutral” to CTMX, setting the target price at $1.50 in the report published on July 07th of the current year.
CTMX Trading at 26.48% from the 50-Day Moving Average
After a stumble in the market that brought CTMX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.45% of loss for the given period.
Volatility was left at 8.17%, however, over the last 30 days, the volatility rate increased by 14.33%, as shares surge +31.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.82% upper at present.
During the last 5 trading sessions, CTMX rose by +47.93%, which changed the moving average for the period of 200-days by -60.31% in comparison to the 20-day moving average, which settled at $1.3865. In addition, CytomX Therapeutics Inc. saw -58.66% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at CTMX starting from Peterson Amy C., who sale 7,463 shares at the price of $1.42 back on Jul 20. After this action, Peterson Amy C. now owns 62,690 shares of CytomX Therapeutics Inc., valued at $10,612 using the latest closing price.
Landau Jeffrey B, the Chief Business Officer of CytomX Therapeutics Inc., sale 4,206 shares at $1.42 during a trade that took place back on Jul 20, which means that Landau Jeffrey B is holding 30,725 shares at $5,982 based on the most recent closing price.
Stock Fundamentals for CTMX
Current profitability levels for the company are sitting at:
- -120.42 for the present operating margin
- +91.61 for the gross margin
The net margin for CytomX Therapeutics Inc. stands at -120.17. Equity return is now at value -166.30, with -34.80 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 2.92.